First Turn Management LLC Has $28.11 Million Stock Holdings in Ascendis Pharma A/S $ASND

First Turn Management LLC cut its position in Ascendis Pharma A/S (NASDAQ:ASND) by 9.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 131,808 shares of the biotechnology company’s stock after selling 14,483 shares during the quarter. Ascendis Pharma A/S accounts for 3.2% of First Turn Management LLC’s portfolio, making the stock its 15th biggest holding. First Turn Management LLC’s holdings in Ascendis Pharma A/S were worth $28,107,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Rhumbline Advisers grew its stake in shares of Ascendis Pharma A/S by 4.0% in the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 55 shares during the period. Certuity LLC grew its position in Ascendis Pharma A/S by 5.7% in the 4th quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 63 shares during the period. Farther Finance Advisors LLC grew its position in Ascendis Pharma A/S by 15.1% in the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 72 shares during the period. Jones Financial Companies Lllp grew its position in Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares during the period. Finally, New Wave Wealth Advisors LLC grew its position in Ascendis Pharma A/S by 3.7% in the 4th quarter. New Wave Wealth Advisors LLC now owns 2,518 shares of the biotechnology company’s stock valued at $537,000 after purchasing an additional 89 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ASND. Oppenheimer reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday. Wedbush reissued an “outperform” rating and issued a $273.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th. Wolfe Research reissued an “outperform” rating and issued a $260.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Barclays lifted their price target on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Finally, Wells Fargo & Company reduced their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $295.39.

Insiders Place Their Bets

In other news, Director Jean Jacques Bienaime acquired 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were purchased at an average cost of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director directly owned 400 shares of the company’s stock, valued at $95,120. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Flemming Steen Jensen sold 19,460 shares of Ascendis Pharma A/S stock in a transaction on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by insiders.

Ascendis Pharma A/S Price Performance

ASND opened at $218.06 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72. The company has a market capitalization of $13.60 billion, a price-to-earnings ratio of 25.15 and a beta of 0.39. The firm’s fifty day moving average price is $232.15 and its two-hundred day moving average price is $223.57. Ascendis Pharma A/S has a 1 year low of $160.86 and a 1 year high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to analysts’ expectations of $362.47 million. As a group, analysts anticipate that Ascendis Pharma A/S will post 14.25 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.